S

Santen

Develops medicines and devices for eye health

QA Digital Experience Intern

InternshipUpdated on 10/23/2026
No salary listed
Bachelor's, Master's
Amsterdam, Netherlands
HybridHybrid attendance depends on local office policy; office days are not specified.
Product & Experience DesignUX Research

About the job

Requirements
  • Currently pursuing a Bachelor's or Master's degree in a relevant field, such as User Experience (UX/UI) Design, Digital Product Design, Communication and Multimedia Design, Human-Computer Interaction, Information Management, Digital Marketing, Industrial or Product Design, or a related digital, communication, or technology-focused discipline.
  • Must remain registered as a student for the entire internship; formal documentation may be requested.
  • Knowledge of SharePoint Online and Microsoft 365.
  • Experience with Power BI and data visualization.
  • Understanding of user research and usability testing methodologies.
  • Basic HTML and CSS knowledge.
  • Interest in artificial intelligence and digital workplace innovation.
  • Able to work independently while collaborating with diverse stakeholders.
Responsibilities
  • Redesign and optimize the EMEA QA SharePoint site structure, navigation, and overall user experience.
  • Conduct user experience assessments, user journey mapping, and usability improvement activities.
  • Create digital content, visual communications, infographics, and communication materials.
  • Support Power BI integration and KPI/dashboard visualization initiatives.
  • Contribute to digital Quality Management System solutions and process improvements.
  • Develop communication materials that promote Quality Culture, Continuous Improvement, and strategic EMEA QA projects.
  • Explore and support AI-enabled communication and knowledge management solutions.
  • Collaborate with stakeholders across Quality Assurance, IT, Communications, and Operational Excellence functions.
Desired Qualifications
  • Communication, content creation, and visual storytelling skills.

About the company

S

Santen

View
Website

Santen researches, develops, manufactures and markets medicines and medical devices for eye care. Its portfolio includes prescription treatments for glaucoma, dry eye, allergies and other eye conditions, alongside nonprescription products and surgical devices. The company combines laboratory research and clinical development with formulation, quality control and manufacturing to bring products to healthcare markets. It earns revenue from pharmaceutical and device sales, working through regional subsidiaries and commercial partners to supply healthcare professionals, pharmacies and other customers. Founded in 1890, Santen is headquartered in Osaka, Japan, and sells products internationally.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

N/A

Founded

1890

Get referred to Santen

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Santen's Western Europe Quality Lead role offers a €112,100 to €154,130 base salary, depending on experience and location.
  • Santen launched Rhopressa eye drops in Japan in August 2026, adding a commercial glaucoma product.
  • Santen's Shiga production center supplies eye-care products to Japan, Europe, Korea and other Asian markets.

What critics are saying

  • Santen's revenue fell 2.8% to ¥291.6 billion in the year ended March 2026, despite higher operating profit.
  • Santen's France Medical Science Liaison role requires up to 70% domestic travel, plus occasional international travel.
  • Santen's Amsterdam quality internship requires continuous student enrollment and at least five months of full-time work.

What makes Santen unique

  • Santen concentrates basic research, nonclinical studies and formulation research at its Nara Research and Development Center.
  • Santen's Dropaid delivery aids are designed specifically for its single-dose and preservative-free multidose eye-drop containers.
  • Santen's Preserflo MicroShunt is a CE-marked surgical implant designed to drain aqueous fluid from the eye.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Flexible Work Hours

Company News

AD HOC NEWS
Oct 20th, 2026
Santen schedules JPY 21.00 dividend payment for Santen stock.

Santen schedules JPY 21.00 dividend payment for Santen stock. Published on 10/20/2026 at 18:40 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS Santen stands 17.82 percent below its EUR 11.90 52-week high. Santen stock costs EUR 9.78 on October 20, 2026 at 6:34 p.m. CEST. Dividend and subsidiary update. * Santen has scheduled a JPY 21.00 per-share dividend for November 30, 2026. * Santen disclosed a consolidated subsidiary bankruptcy petition on October 16, 2026. * Santen stock costs EUR 9.78 at Lang & Schwarz on October 20, 2026, 17.82 percent below its EUR 11.90 52-week high. Santen Pharmaceutical (JP3336000009) has scheduled a JPY 21.00 per-share dividend for payment on November 30, 2026, according to a September 22 update from Simply Wall St. At Lang & Schwarz, Santen stock was trading at EUR 9.78 on October 20, 2026 at 6:34 p.m. CEST. Discover more Invest in Stocks Order Contacts Track Biotech The dividend is due to be paid on November 30, 2026, while the ex-dividend date was September 29, 2026. The payment gives investors a dated shareholder-return item separate from the company's operating updates. Subsidiary petition adds a risk item. Santen disclosed a petition for the commencement of bankruptcy proceedings involving a consolidated subsidiary on October 16, 2026. The notice appears in the company's investor-relations materials, linked through Santen. The available notice identifies the legal process but does not provide a quantified earnings effect. Stock sits below its yearly high. The euro quotation is EUR 2.12 below the EUR 11.90 52-week high and EUR 1.73 above the EUR 8.05 low. That places the stock 17.82 percent below its high and 21.49 percent above its low, using the 52-week range published for the Frankfurt quotation on October 15, 2026. Santen's market capitalization was JPY 555.0 billion on October 20, 2026, while its Tokyo price was JPY 1,727.50. The Tokyo quotation was 0.06 percent above the previous session's JPY 1,726.50, a separate home-market measure from the euro quotation. Results date follows the dividend. Santen is scheduled to report its second-quarter fiscal 2027 results on November 5, 2026, according to the dated company-event record carried by Simply Wall St. The November reporting date comes before the November 30 dividend payment and gives the next scheduled point for a fresh operating update. What the price position indicates. The current euro quotation is closer to the yearly low than the yearly high, while the home-market valuation shows a price-to-earnings ratio of 14.54. For investors, the next useful comparison will be whether the November results change that valuation or leave the dividend as the clearer near-term shareholder-return fact. Trading position. Santen stock was trading at EUR 9.78 at Lang & Schwarz on October 20, 2026 at 6:34 p.m. CEST, 17.82 percent below the EUR 11.90 52-week high. The further course of trading is shown by the continuously updated real-time quote of Santen stock. Discover more Start Investing Santen market profile. * Company: Santen Pharmaceutical Co., Ltd. * ISIN: JP3336000009 * Ticker: 4536 * Primary exchange: TSE * Price Lang & Schwarz (as of October 20, 2026, 6:34 p.m. CEST): EUR 9.78 * Market capitalization: JPY 555.0 billion (as of October 20, 2026) * 52-week range: EUR 8.05-EUR 11.90 (as of October 15, 2026) * Sector / Industry: Healthcare / Drug Manufacturers - General Sponsored Ad Santen Pharmaceutical stock: new analysis - 23 October. Fresh Santen Pharmaceutical information released. What's the impact for investors? Our latest independent report examines recent figures and market trends. Disclaimer regarding our articles: This is not investment advice, nor is it a recommendation to buy or sell. Information regarding prices, companies, and markets is provided without guarantee; changes may occur at any time. Stock market transactions can result in significant losses. Our articles are created and reviewed, in whole or in part, automatically with the assistance of AI. en | JP3336000009 | SANTEN | boerse | 70376088 | bgmi

The Japan Times
Oct 8th, 2026
Santen in Spain: Advancing eye care through long-term know-how.

Santen in Spain: Advancing eye care through long-term know-how. * BRIDGES BY SMS * SHARE Oct 9, 2026 Preventing avoidable vision loss and addressing childhood myopia guide Santen's work in Spain and worldwide. Founded in Osaka in 1890, the Japanese pharmaceutical company develops treatments and partnerships to advance eye care. "Our Japanese heritage gives us something very valuable - a long-term perspective," said Fernando Alvarez, general manager of Santen Spain. Its founding spirit of "Tenki ni sanyo suru" (exploring the secrets and mechanisms of nature in order to contribute to people's health), reflects a commitment to applying nature and science to improve people's health. Its specialized scientific expertise supports a clear purpose: helping people see better and live happier lives. In treating glaucoma, Santen collaborates with the Spanish Glaucoma Society and healthcare organizations on GlauCCare, a hospital certification initiative aimed at raising standards. Alvarez emphasizes earlier diagnosis and stronger coordination throughout care. Childhood myopia is another priority, with regular screening, healthy visual habits and appropriate treatment supporting earlier intervention. Time outdoors forms part of those healthy habits. Santen works with ophthalmologists, patient organizations and the eye care community to support children and families, including through collaboration on the children's booklet Myopia Explorers. These partnerships aim to translate scientific evidence into practical support for patients. "If we want to improve outcomes, we need to understand the patient journey, not just the product journey," Alvarez said. This approach also informs staff development and long-term relationships across Spain's healthcare system. Alvarez attributes Santen Spain's performance to trusted customer relationships, ownership and teamwork. This people-centered culture is also reflected in Santen's recognition under ISO 53800 for gender equality, its recognition as an age-friendly employer and, most recently, its 25th place ranking among the 100 Best Companies to Work For in Spain in 2026 by El Mundo's Actualidad Economica. Spain's highly specialized ophthalmology community and established healthcare system offer opportunities to develop practices that can benefit Santen internationally. Developing talent with a global mindset supports that ambition. "Looking ahead, our ambition is to keep advancing eye health by turning insight and innovation into meaningful solutions, so that more people can see and experience the world more fully," Alvarez said.

JapanNews24
Aug 5th, 2026
Santen joins Global Summit for Eye Health as High Impact Partner - japan Industry News.

Santen joins Global Summit for Eye Health as High Impact Partner - japan Industry News. August 5, 2026 Discover more Law Enforcement Machine Learning & Artificial Intelligence Japanese Cuisine Santen Pharmaceutical Co., Ltd. introduced its participation as a High Impact Partner within the inaugural Global Summit for Eye Health, set to happen on November 2, 2026, in Antigua & Barbuda. The summit, organized by the International Agency for the Prevention of Blindness (IAPB) in collaboration with the World Health Organization (WHO), goals to handle the worldwide problem of imaginative and prescient impairment. The occasion will see the launch of the Global Eye Health Compact, a brand new framework designed to speed up progress in eye well being by means of measurable commitments from governments and organizations. Santen's position as a High Impact Partner entails shaping the compact and unveiling its world eye well being dedication through the summit. Rie Nakajima, Director of the Board and Chief Operating Officer of Santen Global, emphasised the significance of collaborative efforts in tackling imaginative and prescient impairment. Nakajima said, "No single organization can solve the growing burden of vision impairment alone. By working alongside governments, healthcare professionals, patient organizations, and global partners, we can help strengthen eye health systems, improve access to quality eye care, and deliver lasting benefits for people around the world." Santen's involvement on the summit builds on its longstanding collaboration with IAPB and different companions within the eye well being neighborhood. The firm has been energetic in initiatives to advance childhood myopia and promote wholesome eye well being habits for kids. Peter Holland, CEO of IAPB, welcomed Santen's participation, noting that collaboration is important to delivering eye care providers at scale and velocity. Holland commented, "Only by working together like this can we deliver eye care services at scale and speed to end avoidable or treatable sight loss." The summit will convey collectively heads of presidency, ministers, worldwide organizations, civil society, and private-sector leaders to set concrete commitments for strengthening eye well being providers worldwide. The aim is to align world motion and speed up progress to succeed in over 1 billion folks dwelling with avoidable sight loss. Santen's participation within the summit underscores its dedication to advancing eye well being and addressing one of many world's most ignored public well being challenges. With greater than 135 years of dedication to eye well being, the corporate goals to contribute considerably to the conclusion of improved world eye well being outcomes. Discover more Demographics Journalism & News Industry Crime & Justice

Santen Pharmaceutical
Aug 5th, 2026
Santen joins inaugural Global Summit for Eye Health as high-impact Partner.

Santen joins inaugural Global Summit for Eye Health as high-impact Partner. Osaka, Japan - 5 August 2026 - Santen Pharmaceutical Co., Ltd. today announced it will join the inaugural Global Summit for Eye Health as a High Impact Partner, marking another step in the company's long-standing commitment to advancing eye health worldwide. Organized by the International Agency for the Prevention of Blindness (IAPB) in technical collaboration with the World Health Organization (WHO), the Summit will bring together heads of government, ministers, international organizations, civil society, and private-sector leaders in Antigua & Barbuda, a Caribbean island nation on 2 November 2026. Together, they will launch the Global Eye Health Compact, a new global framework designed to accelerate progress through measurable commitments from governments and organizations. As a High Impact Partner, Santen helps shape the Global Eye Health Compact and, at the Summit, will unveil its global eye health commitment, outlining how the company will contribute to improving eye health over the coming years. Despite being essential to education, employment, independence, and healthy aging, eye health remains one of the world's most overlooked public health challenges. More than one billion people worldwide continue to live with avoidable vision impairment[*1], highlighting a critical gap between available solutions and access to care. Addressing this challenge requires coordinated action across prevention, early diagnosis, treatment, and public policy. Rie Nakajima, Director of the Board, Chief Operating Officer of Santen Global, commented: "No single organization can solve the growing burden of vision impairment alone. By working alongside governments, healthcare professionals, patient organizations, and global partners, we can help strengthen eye health systems, improve access to quality eye care, and deliver lasting benefits for people around the world. With more than 135 years of dedication to eye health, Santen is proud to join this global coalition." Santen's participation builds on its longstanding collaboration with IAPB and partners across the eye health community to strengthen policy, raise awareness, and promote early action, including initiatives to advance childhood myopia and encourage healthy eye health habits for children. Peter Holland, CEO, IAPB, commented: "We welcome Santen's participation in the first Global Summit for Eye Health and look forward to continuing our collaboration to strengthen eye health policies and improve outcomes for over 1 billion people who experience vision problems worldwide. Only by working together like this can we deliver eye care services at scale and speed to end avoidable or treatable sight loss." About Santen Santen is a global pharmaceutical company committed to advancing eye health and improving lives through better vision. Founded in 1890 in Osaka, Japan, Santen makes use of more than 135 years of experience in research and development, manufacturing, and marketing of pharmaceuticals and medical devices to help people around the globe maintain and improve their eye health. Santen focuses exclusively on eye health and its portfolio includes glaucoma, dry eye, infection, allergy, age-related macular degeneration, and myopia. Santen's products and services are available in more than 60 countries and regions. Guided by its Core Principle "Tenki ni sanyo suru" - Exploring the secrets and mechanisms of nature in order to contribute to people's health - Santen combines its expertise with deep patient focus to contribute to the realization of "Happiness with Vision." For more information, please visit https://www.santen.com/en. About the Global Summit of Eye Health On 2 November, Antigua and Barbuda will host the world's first Global Summit for Eye Health - the moment when governments, partners and global leaders unite for the first time to ensure everyone, everywhere can access the eye care they need. At the Summit, countries will set out concrete commitments to strengthen eye health services worldwide, aligning global action and accelerating progress to help reach over 1 billion people living with avoidable sight-loss. For more information, please visit Global Summit for Eye Health - Making the world see the value of vision About IAPB IAPB is the overarching alliance for the global eye health sector, with more than 250 member organisations in over 100 countries working together for a world where everyone has universal access to eye care. IAPB believes in a world in which no one is needlessly visually impaired, where everyone has access to the best possible standard of eye health; and where those with irreparable sight loss achieve their full potential. Its key priorities are global advocacy, campaigning on a different level, sharing knowledge, and strengthening the network: www.iapb.org. Partnership Transparency Statement Santen supports the activities described in this initiative through collaboration with IAPB. The organizations maintain independent governance and decision-making. The views expressed by IAPB are its own and do not necessarily reflect those of Santen. For media inquiries: Santen Pharmaceutical Co., Ltd. Corporate Communications Email: [email protected] This press release has been published in Japanese, Simplified Chinese and English languages and in the event of any inconsistency, the English version shall prevail.

Santen Pharmaceutical
Apr 17th, 2026
Santen China signs exclusive distribution and promotion agreement for five marketed Glaucoma Eyedrops products in the Chinese Mainland.

Santen China signs exclusive distribution and promotion agreement for five marketed Glaucoma Eyedrops products in the Chinese Mainland. April 17, 2026 - Osaka, Japan - Santen Pharmaceutical Co., Ltd. (hereinafter Santen) announced today that Santen China has entered into a distribution and promotion agreement with AbbVie for five marketed glaucoma eyedrops in the Chinese Mainland. Under the agreement, Santen China will receive exclusive distribution rights and conduct promotional activities in the Chinese Mainland for Glaucoma Eyedrops Alphagan(R), AlphaganP(R), Lumigan(R), Ganfort(R) and Combigan(R). A pillar of AbbVie's glaucoma eyedrop product portfolio, the brimonidine tartrate ophthalmic solution (Alphagan(R) and AlphaganP(R) features a dual intraocular pressure (IOP)-lowering effect that suppresses aqueous humor production and promotes aqueous humor outflow via the uveoscleral pathway; it is recommended as one of the first-line treatments under Asia-Pacific Glaucoma Society guidelines.[1] These products will synergize with existing Santen prostaglandin-related products while creating a complementary, multi-MoA (Mechanism of Action) glaucoma portfolio and strengthening the Company's business foundation in the China market. Glaucoma is a disease in which the optic nerve is damaged by increased IOP, causing progressive visual field loss; if not treated appropriately, it can lead to blindness.[2,3] As of 2020, the number of patients with primary glaucoma worldwide exceeded 76 million, and this number is expected to exceed 100 million by 2040.[4] The number of glaucoma patients in China numbered more than 21.8 million, leading to 5.67 million cases of blindness as of 2020.[2] By fully leveraging its proven strong commercial presence in China's glaucoma market, Santen will capitalize on this agreement with AbbVie to unleash the growth potential of the glaucoma products. While focusing on addressing clinical challenges in glaucoma treatment, Santen is committed to providing eye care professionals with new therapeutic strategies and approaches, empowering them to elevate the standard of glaucoma treatment in China, and ultimately benefit millions of patients. References * Asia-Pacific Glaucoma Guidelines, 4th Edition. 2024 * Chinese Glaucoma Guideline (2020) [J]. Chinese Journal of Ophthalmology, 2020, 56(8): 573-586. * Weinreb RN, et al. JAMA. 2014;311(18):1901-1911. * Tham YC, et al. Ophthalmology. 2014;121(11):2081-2090. About Santen Santen is a global pharmaceutical company committed to advancing eye health and improving lives through better vision. Founded in 1890 in Osaka, Japan, Santen makes use of more than 135 years of experience in research and development, manufacturing, and marketing of pharmaceuticals and medical devices to help people around the globe maintain and improve their eye health. Santen focuses exclusively on eye health and its portfolio includes glaucoma, dry eye, infection, allergy, age-related macular degeneration, and myopia. Santen's products and services are available in more than 60 countries and regions. Guided by its Core Principle "Tenki ni sanyo suru" - Exploring the secrets and mechanisms of nature in order to contribute to people's health - Santen combines its expertise with deep patient focus to contribute to the realization of "Happiness with Vision." For more information, please visit https://www.santen.com/en. About AbbVie Founded in 2013, AbbVie is a top 5 research-based global biopharmaceutical company headquartered in North Chicago, Illinois, the USA. AbbVie's mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow. Santen Pharmaceutical Co. strive to have a remarkable impact on people's lives across several key therapeutic areas - immunology, oncology, neuroscience, and eye care - and products and services in its Allergan Aesthetics portfolio. Contact Corporate Communications Santen Pharmaceutical Co., Ltd. E-mail: [email protected] This press release has been published in Japanese, Simplified Chinese and English languages and in the event of any inconsistency, the English version shall prevail.